Humanigen Inc (fka HGENQ) : Is there even any truth to this? Isn&#39...

Is there even any truth to this? Isn't

Leee6 · 2020-10-07T23:06:35.8970000Z

Is there even any truth to this? Isn't the FDA completely independent from the white house? He can talk smack all he wants but the most they can do is pressure them to review these therapeutics, no?

Play Episode

7min

Proactive - Interviews for investors

Solvonis CEO says Awakn shareholder approval of acquisition is a 'great endorsement'

Solvonis Therapeutics PLC CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the proposed acquisition of Awakn Life Sciences following strong shareholder approval. Over 99% of Awakn’s shareholders voted in favour of the transaction, which Tennyson described as a “great endorsement” of the strategic fit and potential of combining the two companies. Solvonis is acquiring Awakn for around £5 million in an all-stock transaction. The deal includes two key clinical-stage programs. The lead candidate, AWKN-001, targets severe AUD in the UK and EU markets. It is currently in phase three trials. According to Tennyson, “People coming on to that trial were sober seven days a year. Those who went through the active arm... achieved on average 86% sobriety in the six months post-treatment.” PharmaVentures, which is advising on the deal, has suggested the asset could potentially deliver up to £60 million in milestone payments and generate double-digit royalties. A second program, AWKN-002, aimed at the US market, is in phase 2B planning and may yield up to £150 million in similar payments if successful. The acquisition is seen as a key step in establishing Solvonis as a UK-based biotech focused on addiction and mental health. Visit Proactive’s YouTube channel for more interviews and updates. Don’t forget to like the video, subscribe to the channel and enable notifications for future content. #SolvonisTherapeutics #AwaknAcquisition #AlcoholUseDisorder #MentalHealthTreatment #BiotechInvesting #ClinicalTrials #AWKN001 #AddictionRecovery #PharmaVentures #InvestorNews

Proactive - Interviews for investors

ZRCN expands global reach as it reinvents stud finder tech for the next generation

ZRCN CEO John Stauss joined Steve Darling from Proactive to discuss the company’s transformation from a family-founded private firm to a publicly traded innovator with global ambitions. ZRCN Inc., the parent of Zircon Corporation, is best known for its electronic stud finders—a product category it has long dominated and now plans to revolutionize once again. Stauss explained how the company has used Silicon Valley R&D to modernize a traditionally stagnant tool sector, solving everyday frustrations like locating wall studs without damaging drywall surfaces. “We solved that problem,” he said, pointing to the company’s long-standing reputation for reliability in wood-frame construction markets. Beyond its classic offerings, ZRCN has broadened its product line to include devices that detect rebar, metal piping, and live AC wiring—addressing growing needs in both residential and commercial settings. These innovations are helping the company gain traction in international markets, expanding beyond North America where it first established its foothold. Looking ahead to 2025, Stauss revealed the company is gearing up to launch a new breakthrough technology that could reinvent the very category it pioneered. “Yes, yes, yes to all of the above,” he said when asked if the company was refining, innovating, and expanding at the same time. This next phase of growth will be driven by a mix of enhanced features, an expanded product portfolio, and wider global penetration. The CEO also reflected on how pandemic-era home improvement booms bolstered demand, and how ZRCN’s resilient supply chain enabled the company to deliver when competitors couldn’t. Now, with the company entering the public markets, investor engagement and transparency are becoming top priorities. #proactiveinvestors #otcqx #zrcn #StudFinder #HomeImprovement #ConstructionTech #DIYTools #InvestorUpdate #SiliconValleyTech #ElectronicSensors #GlobalExpansion #HomeRenovation #SupplyChain

Proactive - Interviews for investors

S&U reports record year for Aspen Bridging as Advantage Motor Finance gets back on track

S&U PLC chairman Anthony Coombs takes Proactive's Stephen Gunnion through the company's full-year results to the end of January 2025. Despite regulatory headwinds in its Advantage Motor Finance division, the company reported stable revenue, with record results from its Aspen Bridging arm. Coombs highlighted the impact of an FCA Section 166 investigation, which added approximately £1.5 million in costs and prompted an £11 million increase in provisions. While these factors significantly reduced profitability in the motor finance business, he expressed confidence that such challenges would not repeat in the coming year. "We've dealt with our customers in a responsible and... Christian-like manner," Coombs said, reflecting on the company's values-driven approach to business. He also noted that internal morale, temporarily shaken during the FCA review, was now recovering strongly. In contrast, the Aspen Bridging division achieved record revenue, profit, and transaction levels. Launched in 2017 to meet demand for bridging and small development finance, the division has proven to be a strategically sound addition to S&U's portfolio. Looking ahead, Coombs expressed cautious optimism for the UK economic landscape, suggesting that interest rates might stabilise. He emphasised the importance of robust underwriting as a defence against economic uncertainty, saying the company has weathered similar conditions in the past eight years. For more company insights, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future updates. #SAndUPLC #AnthonyCoombs #AspenBridging #MotorFinance #FCAReview #FinancialResults2025 #UKFinance #InterestRates #InvestorUpdate #ProactiveInvestors

Proactive - Interviews for investors

Arecor CEO on strong 2024 progress and 2025 milestones

Arecor Therapeutics CEO Sarah Howell talked with Proactive's Stephen Gunnion about the company’s strong progress across its proprietary diabetes and obesity pipeline and partnerships. The discussion followed the release of Arecor Therapeutics’ full-year 2024 results, where Howell detailed advances in AT278 — a highly concentrated, ultra-rapid acting insulin shown to be effective in patients with Type 2 diabetes and high BMI. AT278, according to Howell, delivers faster insulin onset and superior glucose control compared to current market alternatives. “We got more insulin on board faster,” she said, highlighting the product’s pharmacokinetic and pharmacodynamic advantages. She added that the insulin is particularly suited for use in insulin pump therapies, especially for patients requiring high daily doses — a segment traditionally underserved by existing pump solutions. Beyond injectables, Arecor has entered the oral peptide delivery space with a new platform targeting enhanced bioavailability, initially focusing on oral GLP-1 for obesity. Howell noted, “We have overcome the first significant challenges of stabilising the peptide,” using the company’s Arestat technology, with semaglutide development underway to improve upon existing oral GLP-1 drugs like Rybelsus. The company continues to expand its partner network and revenue-generating collaborations. It expects key data from oral peptide studies and a potential strategic partnership announcement for AT278 during 2025. For more insightful updates from biotech and pharma leaders, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications to stay updated! #ArecorTherapeutics #AT278 #InsulinPump #GLP1 #DiabetesTreatment #ObesityDrugs #BiotechNews #PharmaInnovation #Semaglutide #OralDelivery #DrugDevelopment #ProactiveInvestors

Followers	1
Posts	42
Boards Moderated	0
Alias Born	09/18/2020

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Go Ad-Free